The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

BioNTech painted a bleak picture of its operations on Tuesday as the German drugmaker swung to a quarterly loss and announced the departure of its co-founders. BioNTech posted a loss of 1.25 euros a ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $103.80 as of March 4th.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.

BioNTech (NasdaqGS:BNTX) cofounders Ugur Sahin and Özlem Türeci are leaving their roles as CEO and Chief Medical Officer.

As the European Lung Cancer Congress prepares to convene in Copenhagen, BioNTech SE is shifting investor focus toward its expanding oncology portfolio. New clinical data for its antibody-drug ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

The founders of the biotech company that developed Comirnaty, the mRNA-based COVID-19 vaccine sold by BioNTech and Pfizer, will step down and form a new mRNA company. BioNTech said Tuesday that Ugur ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...